Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2021 | MDS: QoL considerations

Sara Tinsley-Vance • 24 Sep 2021
MDS 2021
Myelodysplastic Syndromes

Sara Tinsley-Vance, PhD, APRN, Moffitt Cancer Center, Florida, USA, describes the quality of life (QOL) of patients with myelodysplastic syndromes (MDS). Dr Tinsley-Vance explains that although there are tools to measure the QOL, it is highly subjective and it is thus crucial to ask the patient about their own needs. This interview took place at the 16th International Congress on Myelodysplastic Syndromes, held virtually in 2021.

Disclosures

Sara Tinsley-Vance, PhD, APRN, discloses links to Bristol Myers Squibb, Jazz and Novartis.

More from Sara Tinsley-Vance

4:22
A map to support patients and caregivers on the MDS journey
Sara Tinsley-Vance • 22 Sep 2021
0:35
MDS: the role of the multidisciplinary team
Sara Tinsley-Vance • 22 Sep 2021

Related Videos

2:22
Haplo-SCT for older patients with AML/MDS, and should age be a barrier to transplantation?
Raynier Devillier • 15 Apr 2024
2:31
Emerging treatment options for patients with ESA-refractory MDS: luspatercept & imetelstat
Eva Hellström-Lindberg • 11 Apr 2024
1:49
The unmet needs of patients with VEXAS syndrome
Maël Heiblig • 17 Apr 2024
1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals